Antioxidants

Isotetrandrine
Catalog No: CFN98722

Isotetrandrine is a small molecule inhibitor, on various aspects of LPS-induced inflammation in vitro and in vivo. It dose-dependently suppresses the severity of LPS-induced ALI by inactivation of MAPK and NF-κB, which may involve the inhibition of tissue oxidative injury and pulmonary inflammatory process.

Bergenin
Catalog No: CFN98724

Bergenin is a potent antinarcotic agent, has antiviral ,antifungal, antiarrhythmic, antitumor, antiinflammatory, potent immunomodulatory, antitussive, antiulcerogenic,anti-plasmodial, anti-hepatotoxic and wound healing activities. Bergenin has antidiabetic activity, could be classified as a new group of α-glucosidase inhibitors. Bergenin reduces the expression of NO, TNF-α, IL-1β, and IL-6 proinflammatory cytokines by inhibiting the activation of the NF-κB and MAPKs signaling pathways, and it may represent a novel treatment strategy for mastitis.

DL-alpha-Tocopherol
Catalog No: CFN90041

DL-alpha-tocopherol, a potent inhibitor of phorbol ester induced shape change of erythro- and megakaryoblastic leukemia cells. DL-alpha-tocopherol acetate protects endothelial cell membranes from oxidative damage and disruption and limits the magnitude of haemorrhage and its spread from the subependyma into the ventricles; it also protects human skin fibroblasts against the cytotoxic effect of UVB, and its mechanism seems to be related to inhibition of UV-induced lipid peroxidation or to the antioxidation effect of dl-alpha-tocopherol.

Atranorin
Catalog No: CFN98728

Atranorin shows significant antinociceptive and antiinflammatory activities, it has a relevant redox-active action, acting as a pro-oxidant or antioxidant agent depending on the radical, also, it will exert cytoprotective effects on cells under oxidative stress induced by H(2)O(2). Atranorin has suppression of viability and proliferation in tumour cell lines.

Artemetin
Catalog No: CFN98731

Artemetin has anti-inflammatory, antioxidant and antiapoptotic activities, it protects endothelial function through the activation of ERK1/2 and Akt. Intravenous injection of Artemetin (0.75 mg/kg) significantly reduces the hypertensive response to angiotensin I while increases the average length of bradykinin-induced hypotension.